Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease
Elkholy, M., Aboubakr, H., Abd ElMonem, N., Soliman, R., Masoud, M. (2022). Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease. EKB Journal Management System, 3(1), 313-322. doi: 10.21608/ejmr.2022.222940
Mostafa M. Elkholy; Hossam H Aboubakr; Noha A. Abd ElMonem; Rasha H Soliman; Mohammed M. Masoud. "Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease". EKB Journal Management System, 3, 1, 2022, 313-322. doi: 10.21608/ejmr.2022.222940
Elkholy, M., Aboubakr, H., Abd ElMonem, N., Soliman, R., Masoud, M. (2022). 'Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease', EKB Journal Management System, 3(1), pp. 313-322. doi: 10.21608/ejmr.2022.222940
Elkholy, M., Aboubakr, H., Abd ElMonem, N., Soliman, R., Masoud, M. Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease. EKB Journal Management System, 2022; 3(1): 313-322. doi: 10.21608/ejmr.2022.222940

Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease

Egyptian Journal of Medical Research
Article 24, Volume 3, Issue 1, January 2022, Page 313-322  XML PDF (370.4 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.222940
View on SCiNiTO View on SCiNiTO
Authors
Mostafa M. Elkholyorcid 1; Hossam H Aboubakr2; Noha A. Abd ElMonem2; Rasha H Soliman2; Mohammed M. Masoud2
1Department of Clinical Neurophysiology (Neuro-Diagnostic and Research Center), Faculty of Medicine, Beni-Suef University, Egypt
2Department of Neurology, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
Background: Cognitive decline in patients with Parkinson disease (PD) is a major and progressing health problem that needs reliable and objective assessment tools. Aim: Toexplore the value of EEG spectral ratio as cognitive biomarker in patients with PD. Methods: This cross-sectional case control study enrolled 35 patients with PD and 20 matched healthy controls. All participants were evaluated by quantitative electroencephalography (EEG) spectral power ratio (slow/fast) over different head regions, in addition to clinical and neuropsychological assessment of the patients using Unified Parkinson’s Disease Rating Scale (UPDRS) and Montreal Cognitive Assessment (MoCA). Results: The UPDRS score of the patients was (mean 46.8 ± SD 26.6) and total MoCA score was (mean 20.3 ± SD 5.7). Twenty four of PD patients had cognitive impairment (MoCA <26) and showed significant higher spectral power ratio over the occipital region compared to PD patients with normal cognition (P=0.028). No significant differences of spectral power ratio between PD patients and controls. No significant correlation was found between power spectral ratio, UPDRS and MoCA scores. Conclusions: The occipital EEG spectral power ratio could be used as a complementary tool to neuropsychological assessment in evaluation and follow up of cognitive decline in patients with PD.
Keywords
Quantitative EEG; Spectral power ratio; Parkinson disease, Cognitive decline, Mild cognitive impairment
References
 

  1. Aarsland D. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. Parkinsonism & related disorders 2016;22:144-148.‏
  2. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement disorders 2012; 27(3):349-356.‏
  3. Geraedts VJ, Marinus J, Gouw AA, Mosch A, Stam CJ, van Hilten JJ, et al. Quantitative EEG reflects non-dopaminergic disease severity in Parkinson’s disease. Clinical Neurophysiology 2018;129(8):1748-1755.‏
  4. Stylianou M, Murphy N, Peraza LR, Graziadio S, Cromarty R, Killen A, et al. Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. Clinical Neurophysiology 2018;129(6):1209-1220.‏
  5. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNNP 1992;55:181-184.
  6. Fahn S, Elton R. and Members of the UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn, S, Marsden CD, Calne DB, Goldstein M. Recent Developments in Parkinson’s disease, Vol. 2. Florham Park: McMellam Health Care Information 1987; P. 153-163.
  7. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4): 695–9.
  8. Rahman TA, El Gaafary MM. Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatrics & gerontology international 2009;9(1): 54-61.‏
  9. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, et al. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism & related disorders 2007;13(6):348-354.‏
  10. Fonseca LC, Tedrus GM, Letro GH, Bossoni AS. Dementia, mild cognitive impairment and quantitative EEG in patients with Parkinson's disease. Clinical EEG and neuroscience 2009;40(3): 168-172.‏
  11. Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Berendse HW. Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study. Neurobiology of aging 2013;34(2): 408-418.‏
  12. Fonseca LC, Tedrus GM, Carvas PN, Machado EC. Comparison of quantitative EEG between patients with Alzheimer’s disease and those with Parkinson’s disease dementia. Clinical Neurophysiology 2013;124(10):1970-1974.‏
Statistics
Article View: 260
PDF Download: 247